NCT07235228 Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients
| NCT ID | NCT07235228 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz |
| Condition | Irritable Bowel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multi-center, randomized, double-blind, placebo-controlled, 12 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) on the gut microbiota of IBS patients
Eligibility Criteria
Inclusion Criteria: * diagnosed for Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization * IBS severity assessed with the IBS-Severity Scoring System (IBS-SSS) being ≥ 175 points (indicating medium or severe IBS). Exclusion Criteria: * patients currently taking products containing probiotics or have taken this kind of products during the last 3 months * patients currently taking antibiotics or have taken antibiotics during the last 3 months * patients having a concurrent severe illness (malignancies, uncontrolled hypertension or diabetes, hepatic, renal or cardiac dysfunctions, serious neurological disorders, psychosis, respiratory disorders such as asthma or COPD, hyper- or hypothyroidism * patients having chronic bowel disorders other than IBS, including inflammatory bowel disease, gastroenteritis, stomach and duodenal cancer, celiac disease * patient being tested positive for presence of Clostridioides difficile * patient being pregnant, lactating, or planning to become pregnant during the next 3 months * patient being diagnosed to have a lactose intolerance * patients using motility drugs or dietary fiber supplements withing 2 weeks before study start * patient taking anti-coagulant medication * patients have participated in another clinical trial within the last three months
Contact & Investigator
Jacek Piatek, Prof. Dr.
PRINCIPAL INVESTIGATOR
The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Frequently Asked Questions
Who can join the NCT07235228 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Irritable Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07235228 currently recruiting?
Yes, NCT07235228 is actively recruiting participants. Contact the research team at drpiatek@interia.eu for enrollment information.
Where is the NCT07235228 trial being conducted?
This trial is being conducted at Jarocin, Poland, Jarocin, Poland.
Who is sponsoring the NCT07235228 clinical trial?
NCT07235228 is sponsored by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz. The principal investigator is Jacek Piatek, Prof. Dr. at The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz. The trial plans to enroll 20 participants.